Publicaciones científicas

Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion

Vestergaard C (1), Toubi E (2), Maurer M (3), Triggiani M (4), Ballmer-Weber B (5), Marsland A (6), Ferrer M (7), Knulst A (8), Giménez-Arnau A (9).
(1) Aarhus University Hospital, Aarhus, Denmark.
(2) Bnai-Zion Medical Centre, Haifa, Israel.
(3) Charité-Universitätsmedizin, Berlin, Germany.
(4) University of Salerno, Salerno, Italy.
(5) University Hospital Zurich, Zurich, Switzerland.
(6) Salford Royal Hospital and University of Manchester, Manchester, UK.
(7) Clinica Universidad de Navarra, Pamplona, Spain.
(8) University Medical Centre, Utrecht, The Netherlands.
(9) Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 

Revista: European Journal of Dermatology

Fecha: 23/11/2016

RESUMEN

Chronic spontaneous urticaria (CSU) is characterized by the sudden, continuous or intermittent appearance of pruritic wheals (hives), angioedema, or both for six weeks or more, with no known specific trigger.

The international EAACI/GA2LEN/EDF/WAO urticaria guideline advises standard-dose, second-generation H1-antihistamines as first-line therapy. However, H1-antihistamine treatment leads to absence of symptoms in fewer than 50% of patients.

Updosing of second-generation H1-antihistamines (up to fourfold) as recommended by the EAACI/GA2LEN/EDF/WAO urticaria guideline as second-line therapy, can improve response, but many patients remain symptomatic.

Definitions of response are often subjective and a consensus is needed regarding appropriate treatment targets. There is also an unmet need for biomarkers to assess CSU severity and activity and to predict treatment response.

The EAACI/GA2LEN/EDF/WAO urticaria guideline recommends add-on omalizumab, ciclosporin A (CsA), or montelukast third line in patients with an inadequate response to high-dose H1-antihistamines. Omalizumab is currently the only licensed systemic biologic for use in CSU.

Both omalizumab and CsA are effective third-line CSU treatments; montelukast appears to have lower efficacy in this setting. Omalizumab carries a label warning for anaphylaxis, although no cases of anaphylaxis were reported in the phase III trials of omalizumab in CSU and it is generally well tolerated in patients with CSU. Omalizumab arguably has a better safety profile than CsA.

CITA DEL ARTÍCULO  Eur J Dermatol. 2016 Nov 23

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra